USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: GENOMAS, INC.
Address: 67 JEFFERSON ST
HARTFORD, CT 06106
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $650,338.00 3
SBIR Phase II $4,939,763.00 4

Award List:

Physiogenomic Arrays for Clinical Neuropsychiatry

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gualberto Ruano
Award Amount: $400,000.00
Abstract:
DESCRIPTION (provided by applicant): Neuropsychiatric and neurodegenerative disorders such as schizophrenia, Alzheimer's disease, and depression are genetically complex diseases with multiple contributing genes. There is an urgent need for innovative technologies to study the multi-gene etiology of… More

Gene Markers: Antipsychotic-Induced Metabolic Syndrome

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gualberto Ruano
Award Amount: $107,000.00
Abstract:
DESCRIPTION (PROVIDED BY APPLICANT): This Phase I SBIR Program will develop genetic diagnostic products to improve the safety of atypical antipsychotics (e.g. olanzapine) for treating psychiatric disorders, including schizophrenia. Atypical antipsychotics are prescribed as long-term treatments for… More

DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Gualberto Ruano
Award Amount: $1,331,188.00
Abstract:
DESCRIPTION (provided by applicant): Atypical antipsychotic drugs (AAPs) are indicated in the treatment for schizophrenia, bipolar disorder, psychotic depression and other psychiatric disorders. Their drawback is drug-induced metabolic derangements includi ng weight gain, hyperlipidemia, and… More

DNA Diagnostic System for Statin Safety and Efficacy

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gualberto Ruano
Award Amount: $143,338.00
Abstract:
DESCRIPTION (provided by applicant): Statins are the most prescribed drugs in the world. Their efficacy in primary and secondary prevention of cardiovascular disease as well as beneficial pleiotrophic and anti-inflammatory effects have fostered increasingl y aggressive usage and dosage. Their main… More

DNA Diagnostic System for Statin Safety and Efficacy

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: Gualberto Ruano
Award Amount: $1,008,599.00
Abstract:
DESCRIPTION (provided by applicant): Statins are the most prescribed drugs in the world. Their efficacy in primary and secondary prevention of cardiovascular disease as well as beneficial pleiotrophic and anti-inflammatory effects have fostered increasingl y aggressive usage and dosage. Their main… More

MRI DNA Biomarkers for Neuropsychiatric Disease

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Gualberto Ruano
Award Amount: $1,349,949.00
Abstract:
DESCRIPTION (provided by applicant): Schizophrenia (SZ) is a severely debilitating mental illnesses. It is highly heritable, with concordance rates of 50-80% in monozygotic twins and substantial familial clustering. Phenomenology-based diagnostic systems i n psychiatry have serious limitations… More

System for DNA-Guided Optimization and Personalization of Statin Therapy

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Gualberto Ruano – 860-545-3773
Award Amount: $1,250,027.00
Abstract:
DESCRIPTION (provided by applicant): Currently 30 million Americans with elevated cholesterol receive statin therapy, making statins the most prescribed drug class in the U.S. Statin Induction and Neuro-Myopathy (SINM), the balance of potency and safety, is the main clinical management challenge of… More